Pevaryl 1% spray skin solution - antifungal 30 ml

Product Description

Skin Spray Solution.

Characteristics

The product is indicated in the treatment of: skin mycoses caused by dermatophytes, yeasts and molds; skin infections caused by Gram-positive bacteria: streptococci and staphylococci; mycotic otitis externa, mycosis of the ear canal (limited to the skin emulsion form); onychomycosis - Pityriasis Versicolor.

Ingredients

Alcoholic solution 100 g of alcoholic skin solution contain the active ingredient: econazole nitrate 1.0 g

Excipients

Ethyl alcohol; propylene glycol; perfume no. 4074; tris(hydroxymethyl)aminomethane.

Contraindications

Pevaryl is contraindicated in patients with known hypersensitivity to the active ingredient or to any of the excipients.

Directions for use

Apply morning and evening to the infected skin areas, massaging gently until the fungus has completely disappeared (1-3 weeks). It is recommended to continue application for a few days after the mycosis has disappeared. Intertriginous spaces (e.g., interdigital spaces of the foot, buttock folds) in the moist state should be cleaned with gauze before application. In the treatment of onychomycosis, an occlusive dressing is recommended.

In the treatment of otomycosis (only if there is no lesion of the eardrum), instill 1-2 drops of PEVARYL skin emulsion 1-2 times a day, or insert a strip of gauze soaked in it into the external auditory canal.

The drug works overnight and should be removed by washing the following morning.

If Pityriasis Versicolor has not been eradicated after 15 days of completing the applications, repeat the treatment. To avoid relapses, it is recommended to continue the treatment after 1 and 3 months. Regular use of PEVARYL as prescribed is of decisive importance for healing.

Warnings

For external use only. Not for ophthalmic or oral use. If a sensitization or irritation reaction occurs, discontinue use of the product. Econazole nitrate powder contains talc. Avoid inhalation to prevent airway irritation, especially in children and infants. When applying the spray form, avoid inhalation and excessive or improper use.

Interactions

Econazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite limited systemic availability after cutaneous application, clinically relevant interactions with other medicinal products may occur, and some have been reported in patients taking oral anticoagulants, such as warfarin and acenocoumarol.

In patients taking oral anticoagulants, caution should be exercised and the INR should be monitored more frequently. Dosage adjustment of the oral anticoagulant may be necessary during treatment with econazole and after its discontinuation.